

UK SACT Board Annual Report 2025

UK SACT Board Co-Chairs for 2025 - *Netty Cracknell and Joseph Williams*



The UK SACT Board Website - [Home | UK SACT Board](#)

The UK SACT Board Full Membership List - [Members | UK SACT Board](#)

About the UK Systemic Anti-Cancer Therapy (SACT) Board

The professional bodies whose members are involved in the delivery of systemic anti-cancer therapy (SACT) services for cancer treatment – The Royal College of Radiologists (RCR), the Royal College of Physicians (RCP), the Association of Cancer Physicians (ACP), the British Oncology Pharmacy Association (BOPA), the UK Oncology Nursing Society (UKONS) and the British Society for Haematology (BSH) – plus our co-opted members - have a key interest in ensuring the ongoing delivery and development of high quality SACT services for cancer patients UK-wide.

The “UK Chemotherapy Board” was established in 2013 to deliver this aspiration. The Board was renamed the “UK Systemic Anti-Cancer Therapy Board” in November 2022 to reflect the increased use of systemic anti-cancer therapies in cancer management (see Purpose/Remit below). SACT includes (but is not limited to) cytotoxic chemotherapy, targeted therapies and immunotherapy.

Purpose/Remit

The main purpose of the UK SACT Board (UKSB) is to provide guidance, oversight and support for the continuing development of SACT services in the UK. This may be achieved by working with other bodies (for example, NHS-England and/or devolved nations equivalents, the National Institute for Health and Care Excellence, the Care Quality Commission) or by commissioning individual pieces of work as required.

Strategic themes to which the Board is likely to contribute include:

- Production of national guidance
- The commissioning of SACT services at a national and regional/local level

- Multi-professional workforce development
 - Reducing unnecessary variation in practice
 - Ensuring equity of access to safe, high-quality SACT services
 - Supporting and encouraging research.
-

Strategic Oversight and Governance in 2025

The UK SACT Board (UKSB) continued its role in providing national leadership and strategic direction for systemic anti-cancer therapy (SACT) services across the UK. Both Joseph Williams and Netty Cracknell were the UKSB Co-Chairs for 2025. The Board continues to comprise of representatives from five professional bodies (and many more co-opted members) and includes input from all four nations of the UK, ensuring a collaborative and inclusive approach to cancer service development. For the first time, The British Society of Haematology (BSH) have joined the board as a board member (making the professional bodies of the UKSB to six), and will have full membership from November 2025 – welcome to The British Society of Haematology. Furthermore, the United Kingdom Association of Supportive Care in Cancer (UKASCC) has joined as a co-opted member of the board in November 2025.

Recent Key Publications and Guidance

The UKSB published several important documents to support clinical practice and service delivery:

- The recruitment for the UK SACT Board National Protocol Pilot was completed in 2025 with Pharmaceutical Press – the project is due to start at the end of 2025, early 2026.
- Anaphylaxis and Hypersensitivity Reactions Guidance (August 2025): A comprehensive framework for managing infusion-related reactions in patients receiving intravenous SACT.
- SACT Protocol Content Recommendations (May 2025): Standardized guidance on essential information to be included in SACT protocols
- Good Practice Guidelines for Immuno-Oncology Medicines (Updated May 2024): Practical recommendations for safe implementation of immunotherapies

Further publications are being worked on and are near publication. These include:

- Standardising patient reviews for SACT
- National extravasation guidelines
- Intrathecal Chemotherapy Standards

In 2025 numerous projects were brought to the board and are also being worked on. These include consensus guidelines for:

- Cardio Oncology (UK consensus guideline is needed to provide achievable recommendations for all systemic anti-cancer therapies with cardiotoxic potential)
- Calcium folinate (folinic acid) dosing and preparation across the UK
- Use of GLP-1 Agonists in Cancer Patients

Annual Conference – November 2025

The UK SACT Board Annual Conference will be held on 27th November 2025 at the Pullman London St Pancras Hotel. Chaired by Joseph Williams and Netty Cracknell the event will bring together experts in cancer pharmacy, nursing, Haematology, and medical education.

[Find out more about the UK SACT Board](#)

Further information about the work and activities of the Board – including it's the full terms of reference, membership, its publications and its annual conference – is available on the website -[Home | UK SACT Board](#) (supported and maintained by BOPA).

For any queries about the UKSB or if therefore are any issues that you feel the Board could assist with, please get in touch via [Contact Us | UK SACT Board](#) or by emailing uksactboard@bopa.org.uk